# Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

> **NCT05309629** · PHASE2 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT05309629
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-18
- **Primary completion:** 2023-02-01
- **Final completion:** 2024-12-13
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05309629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05309629, "Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05309629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*